Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Phase 2/3 Completed 19 enrolled Hospital Universitario Dr. Jose E. Gonzalez

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the combination of low doses of alemtuzumab and rituximab are effective in the treatment of patients with autoimmune cytopenias who has failed on steroids, relapsed after steroids withdrawal or required continuous steroids treatment.

Timeline

Start: 2008-08
Primary completion: 2010-08
Completion: 2010-08

Publications

Gomez-Almaguer D, Solano-Genesta M, Tarin-Arzaga L, Herrera-Garza JL, Cantu-Rodriguez OG, Gutierrez-Aguirre CH, Jaime-Perez JC. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010 Dec 2;116(23):4783-5. doi: 10.1182/blood-2010-06-291831. Epub 2010 Sep 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	10 mg	Subcutaneous
Subject	Rituximab	Monoclonal antibody	100 mg	Intravenous

Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias

Summary

Timeline

Publications

Drugs

Indications